Crispr Therapeutics is trading 4.3% down at $51.95, amid a broad market pullback.
- The Nasdaq Composite is down 1.42% and the S&P 500 is down 0.67%, with technology stocks leading declines.
- Higher yields and geopolitical tensions are weighing on risk appetite.
- No August 18, 2026 company-specific announcement or stock-movement explanation was identified. Its latest release was August 3, covering Q2 results and pipeline updates, rather than today’s decline.